Research programme: obesity therapeutic - BioLineRxAlternative Names: BL-3020
Latest Information Update: 03 Mar 2010
At a glance
- Originator Hebrew University of Jerusalem
- Developer BioLineRx
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Obesity
Most Recent Events
- 20 Jul 2006 Preclinical trials in Obesity in Israel (PO)